AAV Capsid Variants for CNS Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering genes to the adult central nervous system (CNS) are inefficient due to low transduction efficiency of natural adeno-associated virus (AAV) variants and neutralization by pre-existing antibodies, limiting their clinical application.
Innovation Solution
Development of AAV capsid variants with enhanced tropism for CNS and muscle tissues, achieved through specific amino acid sequences and modifications, such as PLNGAVHLY, to improve delivery efficiency and evade antibody neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural AAV variants are used for CNS gene delivery, then the vector maintains low immunogenicity and non-pathogenic nature, but transduction efficiency is too low for clinical applications
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at positions 586-598 of the AAV capsid protein sequence. Specific substitutions (e.g., E586K, D587N, E588K, Q590K, Q592K, Q597K) were made to enhance CNS transduction efficiency while preserving the safety profile of natural AAV vectors. This direct modification of structural parameters resolved the contradiction between low transduction efficiency and safety.
Solution Approach 2:
The patent applies local quality by focusing modifications on specific regions of the capsid protein (positions 586-598) rather than random mutations. This targeted approach to local sequence optimization enabled enhanced brain tropism and transduction efficiency while maintaining the overall safety characteristics of the AAV vector system.
2Productivity
If capsid sequence randomization is used to create variants, then improved tropism to target tissue may be achieved, but capsid neutralization by pre-existing neutralizing antibodies may still prevent treatment
Solution Approach 1:
The patent applies parameter changes by making specific, rational amino acid substitutions in the capsid sequence rather than random mutations. The modified residues (positions 586-598) were selected to alter capsid properties for enhanced CNS penetration while avoiding epitopes recognized by pre-existing neutralizing antibodies, thus resolving the contradiction between improved tropism and antibody neutralization.
3Productivity
If AAV capsids are engineered for improved CNS tropism, then delivery efficiency to brain tissue increases, but the complexity of capsid design and production increases
Solution Approach 1:
The patent applies local quality by limiting modifications to a specific region of the capsid protein (positions 586-598) rather than comprehensive redesign. This focused approach to local sequence optimization achieved enhanced CNS delivery efficiency while minimizing design and production complexity compared to global capsid engineering strategies.
Data Source
AI summary
The disclosure relates to compositions, formulations, and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.